Shan Xing1, Gregory S Calip1, Alex D Leow2, Shiyun Kim3, Glen T Schumock1, Daniel R Touchette1, Todd A Lee4. 1. University of Illinois at Chicago, Department of Pharmacy, Systems, Outcomes and Policy, College of Pharmacy, United States. 2. University of Illinois at Chicago, Department of Psychiatry, College of Medicine, United States; University of Illinois at Chicago, Department of Bioengineering, College of Engineering, College of Medicine, United States. 3. University of Illinois at Chicago, Department of Pharmacy Practice, College of Pharmacy, United States. 4. University of Illinois at Chicago, Department of Pharmacy, Systems, Outcomes and Policy, College of Pharmacy, United States. Electronic address: toddlee@uic.edu.
Abstract
AIMS: To compare adherence and persistence to oral antidiabetic drugs (OAD) between patients who are new users of second generation antipsychotics (SGA) versus new users of other depression therapies in adults with type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD). METHODS: Adults 18-64 years with previously-treated T2DM and MDD (past OAD and SSRI/SNRI use) who are new users of SGA or non-SGA therapies (bupropion, lithium, mirtazapine, thyroid hormone, tricyclic antidepressant) were identified in the 2009-2015 MarketScan® Commercial Claims and Encounters database. Multivariate regression models were used to determine the odds of a ≥10% decline in OAD adherence over 180- and 365-days, and time to OAD discontinuation, adjusting for differences between groups. RESULTS: A total of 8664 (21.5% SGA), 8311 (22.1% SGA), and 17,524 (21.3% SGA) patients met inclusion criteria for the 180-day adherence, 365-day adherence, and persistence cohorts, respectively. Over 180-days, 16.6% of SGA and 13.3% of non-SGA initiators had a ≥10% decline in OAD adherence (adjusted odds ratio [OR] = 1.41, 95% CI 1.21-1.63). Over 365-days, 22.3% of SGA and 18.9% of non-SGA initiators had a ≥ 10% decline (OR = 1.34, 95% CI 1.17-1.53). Time to OAD discontinuation was similar between groups (adjusted hazard ratio = 1.03, 95% CI 0.94-1.12). CONCLUSION: Use of SGA was associated with a 1.3-1.4 times higher odds of a ≥10% decline in OAD adherence. Adherence to OAD is critical for optimal diabetes control and reductions in this magnitude may impact A1C. Close monitoring of OAD adherence after SGA initiation is warranted.
AIMS: To compare adherence and persistence to oral antidiabetic drugs (OAD) between patients who are new users of second generation antipsychotics (SGA) versus new users of other depression therapies in adults with type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD). METHODS: Adults 18-64 years with previously-treated T2DM and MDD (past OAD and SSRI/SNRI use) who are new users of SGA or non-SGA therapies (bupropion, lithium, mirtazapine, thyroid hormone, tricyclic antidepressant) were identified in the 2009-2015 MarketScan® Commercial Claims and Encounters database. Multivariate regression models were used to determine the odds of a ≥10% decline in OAD adherence over 180- and 365-days, and time to OAD discontinuation, adjusting for differences between groups. RESULTS: A total of 8664 (21.5% SGA), 8311 (22.1% SGA), and 17,524 (21.3% SGA) patients met inclusion criteria for the 180-day adherence, 365-day adherence, and persistence cohorts, respectively. Over 180-days, 16.6% of SGA and 13.3% of non-SGA initiators had a ≥10% decline in OAD adherence (adjusted odds ratio [OR] = 1.41, 95% CI 1.21-1.63). Over 365-days, 22.3% of SGA and 18.9% of non-SGA initiators had a ≥ 10% decline (OR = 1.34, 95% CI 1.17-1.53). Time to OAD discontinuation was similar between groups (adjusted hazard ratio = 1.03, 95% CI 0.94-1.12). CONCLUSION: Use of SGA was associated with a 1.3-1.4 times higher odds of a ≥10% decline in OAD adherence. Adherence to OAD is critical for optimal diabetes control and reductions in this magnitude may impact A1C. Close monitoring of OAD adherence after SGA initiation is warranted.
Authors: Frank Petrak; Harald Baumeister; Timothy C Skinner; Alex Brown; Richard I G Holt Journal: Lancet Diabetes Endocrinol Date: 2015-05-17 Impact factor: 32.069
Authors: Tobias Gerhard; Ayse Akincigil; Christoph U Correll; Neil J Foglio; Stephen Crystal; Mark Olfson Journal: J Clin Psychiatry Date: 2014-05 Impact factor: 4.384
Authors: Jay A Brieler; Patrick J Lustman; Jeffrey F Scherrer; Joanne Salas; F David Schneider Journal: Fam Pract Date: 2016-01-07 Impact factor: 2.267
Authors: Bessie Ann Young; Elizabeth Lin; Michael Von Korff; Greg Simon; Paul Ciechanowski; Evette J Ludman; Siobhan Everson-Stewart; Leslie Kinder; Malia Oliver; Edward J Boyko; Wayne J Katon Journal: Am J Manag Care Date: 2008-01 Impact factor: 2.229
Authors: Shivani K Mhatre; Omar Serna; Shubhada Sansgiry; Marc L Fleming; E James Essien; Sujit S Sansgiry Journal: J Manag Care Spec Pharm Date: 2016-11
Authors: Hsien-Yen Chang; Jonathan P Weiner; Thomas M Richards; Sara N Bleich; Jodi B Segal Journal: Am J Manag Care Date: 2012-11 Impact factor: 2.229